|  | [Survey] Bioavailability Toolkit Share insight on the drug developer’s perspective on bioavailability enhancement technologies and the reasoning behind the use of certain technologies in preclinical and early-stage clinical development. The first 50 qualified respondents will receive a $5 Amazon gift card. |
| Direct-to-consumer drug advertising has its fans and foes—but the $6 billion-plus industry has survived decades of challenges in legal, regulatory and public spheres. And mostly because it works. But who’s got the deepest pockets, and for what products—and who’s seeing the biggest returns on those investments? With data from Kantar Media, we look at the top 10 spenders in pharma from last year, across TV, digital, radio, print and billboard ads. That report and our top reads of the week follow below. | |
|
Featured Story | | | Tuesday, February 18, 2020 An industrywide price-fixing probe has snared another former exec—this time a big fish at Novartis' generics business, Sandoz. Hector Armando Kellum, who faces 10 years in prison, agreed to cooperate with the feds, and his plea confirms the Swiss drugmaker's role in the conspiracy. |
|
|---|
|
Top Stories Of The Week Friday, February 14, 2020 In its fourth-quarter earnings out early Friday morning, U.K.-based Big Pharma AstraZeneca has cut two early-stage experimental meds. Direct-to-consumer drug ads tend to strike a dissonant chord. However, fan and foe can count on one thing: Prescription DTC advertising is here to stay. The evidence? Surviving more than 20 years of numerous legal, regulatory and perception challenges on its way to becoming a $6 billion-plus annual industry. Wednesday, February 19, 2020 Warren Buffett often talks about investing in a company's competitive edge or so-called “moat.” Now, the American tycoon thinks he's found a technology fortress in Biogen, and his investment firm is staking $192 million on it—despite the risks associated with its Alzheimer's candidate aducanumab. Wednesday, February 19, 2020 Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Johnson & Johnson and Dana Farber, who joins from Bristol-Myers Squibb. Most recently, he was a vice president and head of the Big Pharma’s Tumor Microenvironment Modulation Thematic Research Center. Tuesday, February 18, 2020 Drugmakers usually target two things: pricing and volume, hopefully both at the same time. But when prices go down, volume's the thing, and GSK and Alcon have pulled off prescription-to-OTC switches in hopes of giving aging brands a boost. Wednesday, February 19, 2020 Abbott and Insulet have launched a collaboration to integrate the former’s continuous glucose monitoring system with the latter’s tubeless insulin pump, with the goal of providing a new, automated diabetes health platform. Tuesday, February 18, 2020 The end is near for a GlaxoSmithKline OTC plant in Pennsylvania and its 260 employees. In fact, it has a date. Tuesday, February 18, 2020 After 17 years at Amgen, head of R&D Sean Harper was ready to get closer to the science. He reunited with his former colleague from Merck and Amgen, Beth Seidenberg, in Los Angeles and set up Westlake Village BioPartners with a $320 million fund. Tuesday, February 18, 2020 Sun Pharmaceutical's latest advice to teens? Take back your face. In its first acne awareness campaign, Sun looks to dispel misconceptions and empower young people ages 12 to 25 to take control of what is often a stigmatizing condition. Eighty-five percent of people who have acne are adolescents, teens and young adults, and studies show that the condition correlates highly with negative psychosocial issues. Tuesday, February 18, 2020 A University of South Florida team discovered that inactivating a subtype of the protein beta-arrestin-2 in mice reduced levels of the toxic brain protein tau. That restored the mechanism by which the brain disposed of tau before it could form the tangles that are a hallmark of neurodegenerative diseases like Alzheimer's and frontotemporal lobar degeneration, they reported. Resources Sponsored by: Research Solutions / Reprints Desk Inc. 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Blue Matter Consulting White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done. Sponsored by: Medidata To conduct a successful trial, do you need to understand the global eConsent Regulatory landscape? Sponsored by: Veeva Learn how data management teams at ICON, Bioforum, and Vertex Pharmaceuticals are creating the spec and casebook in a single step, reducing study build times and effort by over 50%. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. | 
